Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Interest & Investment Income (2019 - 2025)

BridgeBio Pharma's Interest & Investment Income history spans 7 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 7.5% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $19.9 million, up 15.1%, while the annual FY2025 figure was $19.9 million, 15.1% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $4.3 million at BridgeBio Pharma, down from $6.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6.2 million in Q3 2025 and bottomed at $182000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is $4.0 million (2024), against an average of $3.2 million.
  • The largest annual shift saw Interest & Investment Income crashed 79.7% in 2021 before it soared 2148.35% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $182000.0 in 2021, then skyrocketed by 2148.35% to $4.1 million in 2022, then soared by 36.31% to $5.6 million in 2023, then decreased by 16.05% to $4.7 million in 2024, then dropped by 7.5% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Interest & Investment Income are $4.3 million (Q4 2025), $6.2 million (Q3 2025), and $3.9 million (Q2 2025).